SEC Form 4 · accession 0001682852-26-000169
Moderna, Inc. · MRNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shannon Thyme Klinger
Officer — Chief Legal Officer
Period of report
Sep 4, 2026
Accepted (ET)
Sep 8, 2026 · 4:57 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001682852
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 4, 2026 | M | 11,797 | — | A | 87,044 | D | |
| Common Stock | Sep 4, 2026 | F | 5,704 | $148.87 | D | 81,340 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Sep 4, 2026 | M | 11,797 | D | — | — | Common Stock | 11,797 | 106,179 | D |
Explanation of responses
- F1Restricted stock units convert into common stock on a one-for-one basis.
- F2Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
- F325% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter.